Published in Urology on February 04, 2009
Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J (2009) 1.13
Urothelial carcinoma of the bladder: definition, treatment and future efforts. Nat Rev Urol (2011) 1.11
NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest (2015) 0.95
Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J Urol (2011) 0.85
Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS One (2014) 0.85
Nonbilharzial squamous cell carcinoma and transitional cell carcinoma with squamous differentiation of the lower and upper urinary tract. Urol Ann (2012) 0.84
Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors. J Med Life (2014) 0.78
Gene profiling suggests a common evolution of bladder cancer subtypes. BMC Med Genomics (2013) 0.77
Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease? Transl Androl Urol (2016) 0.75
Aggressive squamous cell carcinoma of the bladder associated with a history of large bladder stone - a case report. Clin Case Rep (2017) 0.75
Do pure squamous cell carcinomas and urothelial carcinomas have similar prognosis after radical cystectomy? World J Urol (2012) 0.75
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA (2006) 3.41
Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer (2009) 3.10
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Detection of bladder cancer using a point-of-care proteomic assay. JAMA (2005) 2.88
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology (2010) 1.41
Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. Med Phys (2006) 1.36
Near infrared fluorescence imaging with robotic assisted laparoscopic partial nephrectomy: initial clinical experience for renal cortical tumors. J Urol (2011) 1.35
1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis (2006) 1.20
Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys (2004) 1.17
Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. J Endourol (2012) 1.15
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int (2010) 1.15
Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors. Urology (2012) 1.08
Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res (2005) 1.07
Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int (2012) 1.03
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol (2008) 1.02
Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int (2012) 0.94
A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res (2011) 0.94
Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men. Support Care Cancer (2010) 0.93
The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine (2012) 0.92
Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol (2010) 0.92
Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol (2010) 0.89
Robot-assisted prostate brachytherapy. Med Image Comput Comput Assist Interv (2006) 0.89
Automatic localization of implanted seeds from post-implant CT images. Phys Med Biol (2003) 0.88
Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. Am J Clin Pathol (2004) 0.87
Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion. Urology (2013) 0.85
Methods for prostate stabilization during transperineal LDR brachytherapy. Phys Med Biol (2008) 0.84
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget (2013) 0.84
Metastatic "borderline" papillary ovarian tumor in an intramammary lymph node. Breast J (2002) 0.83
The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int (2011) 0.82
Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. J Steroid Biochem Mol Biol (2010) 0.80
Hybrid dosimetry: feasibility of mixing angulated and parallel needles in planning prostate brachytherapy. Med Phys (2006) 0.79
Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark (2010) 0.78
Bouquet brachytherapy: feasibility and optimization of conically spaced implants. Brachytherapy (2005) 0.78
A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible cystoscopy. Urol Nurs (2013) 0.77
Non-bladder cancer mortality in patients with urothelial cancer of the bladder. Urol Oncol (2011) 0.77
Transrectal sonography in prostate evaluation. Radiol Clin North Am (2006) 0.76
BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urol Oncol (2010) 0.76
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev (2016) 0.76
Crawling wave detection of prostate cancer: preliminary in vitro results. Med Phys (2011) 0.76
Editorial comment. Urology (2012) 0.75
Bilateral testicular epidermoid cysts. J Clin Imaging Sci (2011) 0.75
Cell culture block array for immunocytochemical study of protein expression in cultured cells. Appl Immunohistochem Mol Morphol (2005) 0.75
Factors associated with ureteral burn injury from an electrified guidewire. J Endourol (2008) 0.75
Radical versus partial nephrectomy for a small renal mass: does saving nephrons save lives? Expert Rev Anticancer Ther (2013) 0.75
Lost and now found: retained straight catheter for 20 years. Urology (2010) 0.75